Cytek Biosciences Inc. (CTKB) Stock Falls on Q1 2026 Earnings

Cytek Biosciences Inc. (CTKB) reported results for Q1 2026.

Total revenue rose 6.46% year-over-year to $44.1 million.

Gross profit increased 5.44% to $21.3 million, implying a gross margin of about 48.2%.

Operating loss narrowed 23.29% to $18.5 million.

Net loss attributable to common shareholders improved 65.46% to $18.9 million; diluted EPS was -$0.15 per share.

Cost of sales rose 7.42% to $22.9 million.

Cash used in operating activities narrowed sharply to -$580,000 (up 364.0% year-over-year).

Purchases of property, plant and equipment were -$829,000 (down 2.36% year-over-year).

Cash and cash equivalents stood at $65.7 million (down 31.1% year-over-year).

Total liabilities increased 17.96% to $121.5 million.

Results missed consensus on both top and bottom lines: revenue of $44.1 million versus an expected $45.2 million, and EPS of -$0.15 versus an expected -$0.10.

Shares reacted modestly, declining 2.49% since market close.

Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.

Cytek Biosciences Inc. Hedge Fund Activity

We have seen 75 institutional investors add shares of Cytek Biosciences Inc. stock to their portfolio, and 76 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

BOSTON PARTNERS added 4,971,126 shares (+13369.4%) to their portfolio in Q4 2025, for an estimated $25,104,186
BROWN CAPITAL MANAGEMENT LLC removed 2,885,101 shares (-58.2%) from their portfolio in Q4 2025, for an estimated $14,569,760
WELLINGTON MANAGEMENT GROUP LLP removed 1,776,767 shares (-69.9%) from their portfolio in Q4 2025, for an estimated $8,972,673
MILLENNIUM MANAGEMENT LLC added 1,334,065 shares (+39.0%) to their portfolio in Q4 2025, for an estimated $6,737,028
RUSSELL INVESTMENTS GROUP, LTD. added 841,614 shares (+527.6%) to their portfolio in Q4 2025, for an estimated $4,250,150
CENTERBOOK PARTNERS LP added 729,874 shares (+inf%) to their portfolio in Q1 2026, for an estimated $3,189,549
BANK OF AMERICA CORP /DE/ added 686,001 shares (+403.2%) to their portfolio in Q4 2025, for an estimated $3,464,305

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.

Cytek Biosciences Inc. Government Contracts

We have seen $1,180,000 of award payments to $CTKB over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

BASE PERIOD - MAINTENANCE SERVICES FOR SIX (6) CYTEK AURORA DEVICES TO MAINTAIN OPTIMAL PERFORMANCE IN SUPP...: $233,547
CYTEK AURORA LASER SERVICE CONTRACT -: $109,218
MAINTENANCE/SERVICE CONTRACT FOR CYTEK AURORA FLOW CYTOMETER, S/N U0537/CD141, PRODUCT #N9-90136 (AMBIS 226...: $42,580
PURCHASE OF AMNIS IMAGESTREAM MKII SYSTEM: $39,288
IMAGESTREAM MKII MAINTENANCE CONTRACT COVERAGE.: $38,290

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.

Cytek Biosciences Inc. Analyst Ratings

Wall Street analysts have issued reports on $CTKB in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

TD Cowen issued a "Buy" rating on 01/08/2026
Piper Sandler issued a "Overweight" rating on 11/11/2025

To track analyst ratings and price targets for Cytek Biosciences Inc., check out Quiver Quantitative's $CTKB forecast page.

Cytek Biosciences Inc. Price Targets

Multiple analysts have issued price targets for $CTKB recently. We have seen 2 analysts offer price targets for $CTKB in the last 6 months, with a median target of $6.25.

Here are some recent targets:

Brendan Smith from TD Cowen set a target price of $5.0 on 01/08/2026
David Westenberg from Piper Sandler set a target price of $7.5 on 11/11/2025